Rational Combination of ADC With Chemotherapeutic & Immunotherapeutic Agents
Time: 1:00 pm
day: Pre-Conference Workshop Day - Workshop B
Details:
Antibody Drug Conjugates are the leading modality of cancer therapies that has revolutionized the treatment paradigm of solid tumors. With the rapidly evolving clinical landscape, the number of combination trials involving ADCs have burgeoned in the last few years. Immunotherapeutic agents such as Immune-checkpoint inhibitors and T cell engagers are rapidly emerging therapies for solid tumor targeting. This workshop will allow you to understand the preclinical characterization which is critical for understanding the potential synergism and enable prudent choice of rational clinical combinations of ADCs.
Join this session to gain:
- An evaluation of the evolution of conjugation technologies, linkers and payloads
- A technical understanding of approaches in selecting a combination partner to broaden therapeutic index and achieve durable response
- An outline of toxicity concerns and considerations for combinations
- An overview of the current status of chemotherapeutics and clinical landscape of ADC combinations as well as the current status of Immunotherapeutic agents and clinical landscape of ADC combinations